vTv Therapeutics Inc. (NASDAQ:VTVT) has been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price objective of $18.75 for the company and are forecasting that the company will post ($0.42) EPS for the current quarter, according to Zacks. Zacks has also given vTv Therapeutics an industry rank of 111 out of 265 based on the ratings given to its competitors.
Several research analysts have recently issued reports on VTVT shares. HC Wainwright started coverage on vTv Therapeutics in a research note on Monday, September 26th. They issued a “buy” rating and a $13.00 price objective for the company. Canaccord Genuity reissued a “buy” rating and set a $15.00 target price on shares of vTv Therapeutics in a research report on Friday, August 19th. Finally, Zacks Investment Research raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th.
Shares of vTv Therapeutics (NASDAQ:VTVT) opened at 6.99 on Wednesday. The stock has a 50 day moving average of $6.57 and a 200-day moving average of $5.94. vTv Therapeutics has a 12-month low of $4.84 and a 12-month high of $8.22. The firm’s market capitalization is $67.73 million.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, August 16th. The company reported ($0.47) earnings per share (EPS) for the quarter. On average, equities research analysts predict that vTv Therapeutics will post ($1.61) EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. Kennedy Capital Management Inc. acquired a new position in vTv Therapeutics during the first quarter worth about $282,000. Geode Capital Management LLC boosted its position in vTv Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 34,884 shares of the company’s stock worth $180,000 after buying an additional 822 shares during the last quarter. State Street Corp boosted its position in vTv Therapeutics by 10.9% in the first quarter. State Street Corp now owns 61,239 shares of the company’s stock worth $316,000 after buying an additional 6,000 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock worth $559,000 after buying an additional 18,112 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in vTv Therapeutics by 26.6% in the second quarter. BlackRock Fund Advisors now owns 202,202 shares of the company’s stock worth $1,173,000 after buying an additional 42,520 shares during the last quarter. 12.84% of the stock is owned by institutional investors and hedge funds.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.